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Abstract: Brinzolamide is a white powder commercially formulated as a 1% ophthalmic 
suspension to reduce intraocular pressure (IOP). Pharmacologically, brinzolamide is a highly 
speciﬁ  c, non-competitive, reversible, and effective inhibitor of carbonic anhydrase II (CA-II), 
able to suppress formation of aqueous humor in the eye and thus to decrease IOP. Several clinical 
trials have evaluated its safety and the most commonly ocular adverse events are blurred vision 
(3%–8%), ocular discomfort (1.8%–5.9%), and eye pain (0.7%–4.0%). Brinzolamide has been 
introduced to treat ocular hypertension and primary open-angle glaucoma. In some clinical 
studies it has been estimated that brinzolamide reduced IOP by was about 18%. Brinzolamide 
can be added to beta-blockers and prostaglandins. In the latter combination, because prosta-
glandin derivatives improve the uveoscleral outﬂ  ow but also increase the activity of CA in 
ciliary epithelium with a secondary increase in aqueous humor secretion, and slightly reduce the 
efﬁ  cacy of prostaglandin analogues, theoretically topical CA inhibitors (CAI) decrease IOP by 
inhibiting CA-II, thus improving prostaglandin efﬁ  cacy as well as lowering IOP. Brinzolamide 
could have a secondary possible effect on ocular ﬂ  ow too. Some clinical studies showed a mild 
improvement of ocular blood ﬂ  ow. Theoretically, CAI could give rise to metabolic acidosis, with 
secondary vasodilatation and improvement of  blood ﬂ  ow. Systemic acidosis can occur in the 
setting of oral CAI therapy, and local acidosis within ocular tissues is theoretically possible with 
topical CAI therapy, with the potential for a local increase in ocular blood ﬂ  ow. In conclusion, 
topical CAI treatment has efﬁ  cacy in IOP-lowering ranging from 15% to 20%. From published 
data, brinzolamide can be used as ﬁ  rst-line medication, even if other medications have a higher 
efﬁ  cacy, with few side effects and it is a good adjunctive treatment. In some type of glaucoma 
patients with a vascular dysregulation, topical CAI could have a double effect: reducing IOP 
and improving ocular blood ﬂ  ow.
Keywords: brinzolamide, ocular hypertension, glaucoma, intraocular pressure, ocular blood 
ﬂ  ow, safety, treatment
Brinzolamide is a white powder insoluble in water, commercially formulated as a 1% 
ophthalmic suspension to reduce intraocular pressure (IOP). Brinzolamide empirical 
formula is C12H21N3O5S3 (Figure 1) with a melting point of approximately 131°C 
(Cvetkvic and Perry 2003; Shoji 2007). The commercially available preparation of 
brinzolamide is Azopt® (Alcon Laboratories, Inc, Ft. Worth, Texas, USA), with a 
pH of approximately 7.5 and osmolarity of 300 mOsm/kg (Cvetkvic and Perry 2003; 
Shoji 2007; Iester 2008).
The efficacy of brinzolamide 0.3%–3% bid has been evaluated in several 
randomized double-blind, multicenter comparative clinical trials (March and Ochsner 
2000; Sall 2000; Shin 2000, 2000; Silver 1998, 2000; Michaud and Friren 2001). 
A dose-response study comparing brinzolamide in concentrations of 0.3%, 1%, 2%, and Clinical Ophthalmology 2008:2(3) 518
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3% demonstrated mean IOP reductions of 3 mmHg (11.3%), 
4.3 mmHg (16.1%), 4.4 mmHg (16.1%), and 4.2 mmHg 
(15.4%), respectively. When diurnal IOP was measured, 
brinzolamide 1% or 3% reduced IOP signiﬁ  cantly better than 
brinzolamide 0.3% (Silver 2000).
These observations suggested that the optimal therapeutic 
concentration for IOP reduction was 1%. Its recommended 
dosing frequency is 3 times daily in the US and twice daily 
in the EU and Japan. However, 3 phase III trials have 
reported that brinzolamide 1% bid and tid produced statisti-
cally signiﬁ  cant IOP reductions from baseline, and that both 
treatments were clinically equivalent to one another (Silver 
1998; March and Ochsner 2000; Shin 2000).
Pharmacologically, brinzolamide is a highly speciﬁ  c, non-
competitive, reversible, and effective inhibitor of carbonic 
anhydrase II (CA-II) (DeSantis 2000), able to suppress forma-
tion of aqueous humor in the eye and thus decrease IOP. It can 
catalyze the reversible reaction of water and carbon dioxide 
(CO2) to form negatively charged bicarbonate ions (Maren 
1967). To achieve pharmacological effects, the near total 
inhibition of CA is required (Maren 1967; Kaur et al 2002). 
Brinzolamide is cleared from the aqueous humor and cornea 
with half-lives of approximately 3 and 5 hours respectively. 
Therefore, the cornea acts as a reservoir, providing sustained 
release of the drug to the ciliary processes of the ciliary body 
long after topical dosing (Maren 1967; Kaur et al 2002). In 
human tissues there are 7 different isoenzymatic forms. The 
most active isoenzymatic form is CA-II, which is found mainly 
in the erythrocytes, followed by kidneys, pancreas, eyes, central 
nervous system, and lungs (Maren 1967). In the eye, the enzyme 
is expressed mainly in the ciliary processes of the ciliary body, 
the corneal endothelial cells, and the pigment epithelium.
In the corneal endothelium CA-II plays a role in the 
pumping mechanism, which helps to maintain the relatively 
dehydrated state of the corneal stroma. Inhibition of this mech-
anism may lead to the development of corneal decompensation 
and edema, with secondary impaired vision.
In a randomized, double-blind clinical trial, 372 
glaucomatous and ocular hypertension (OH) patients 
received brinzolamide 1% or timolol 0.5%. After 18 months 
of treatment, no signiﬁ  cant change was found in corneal 
thickness and corneal endothelium cell density (March and 
Ochsner 2000). However, in this study only subjects with 
healthy corneas were included. Some concern remained in 
patients with compromised corneas, because in 2 published 
case reports corneal decompensation has been described in 
patients with keratopathy after treatment with dorzolamide 
(Adamson 1999; Konowal et al 1999).
After topical ocular administration systemic absorption 
of brinzolamide has been demonstrated in the tissues 
of   healthy volunteers (DeSantis 2000). Topically instilled 
brinzolamide enters the blood circulation binding preferen-
tially to CA in the erythrocytes leaving the concentration of 
free brinzolamide in plasma below the quantiﬁ  cation level. 
In the red cells less than 1% of CA-II activity is required to 
maintain physiological function (March and Ochsner 2000). 
Thus in the erythrocytes the concentration of CA inhibitors 
(CAI) was insufﬁ  cient to produce complete saturation of 
CA. In the kidney, free brinzolamide is not sufﬁ  cient to 
inhibit in the proximal convoluted tubules and luminal CA; 
therefore systemic metabolic acidosis should not be obtained 
(see below). Furthermore, the low afﬁ  nity of brinzolamide for 
the other CA isoforms and the low blood concentration may 
explain the low incidence of systemic adverse effects after 
topical administration (March and Ochsner 2000).
Several clinical trials (Zeyen and Caprioli 1993; Silver 
1998; Sall 2000; Shin 2000; Wang et al 2004; Zhao and Chen 
2005; Menon and Vernon 2006) have evaluated the safety 
of brinzolamide 1% ophthalmic suspension. The most com-
monly ocular adverse events were blurred vision (3%–8%), 
ocular discomfort (1.8%–5.9%), and eye pain (0.7%–4.0%). 
Other ocular adverse events occurring at an incidence of less 
than 3% included hyperemia, pruritus, tearing, discharge, 
blepharitis, keratitis, foreign body sensation, dry eye, 
conjunctivitis, and lid margin crusting.
Zhau and Chen (2005) have reported two cases of corneal 
decompensation after 15 months and 2 years of brinzolamide 
therapy. Corneal edema reversed with discontinuation of the 
treatment; however, the reason was difﬁ  cult to assess, and 
neither patient was rechallenged after recovery. No change 
in central corneal thickness was found (Wang et al 2004).
The most common systemic adverse event was taste 
perversion, occurring in 3.0%–7.8% of patients (Silver 1998; 
Sall 2000; Shin 2000). There were no clinically signiﬁ  cant 
changes from baseline in heart rate and blood pressure, 
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and in laboratory values for hematology, blood chemistry, 
or urinalysis variables. In addition, mean total carbonic 
anhydrase activity in red blood cells was reduced by only 
51%–55%. However, one case of systemic metabolic acidosis 
has been described by Menon and Vernon (2006).
Brinzolamide has been introduced to treat OH and 
primary open-angle glaucoma (POAG), which are probably 
two different aspects of the same disease in which IOP is too 
high for the optic nerve head (ONH) structure.
Glaucoma is a multifactorial optic neuropathy character-
ized by the progressive loss of retinal ganglion cells and their 
axons. Clinically, the glaucomatous optic nerve manifests 
progressive enlargement of the optic cup, with commensurate 
progressive thinning of the neuroretinal rim and visual ﬁ  eld 
defects. However, it is possible to lose up to 35% of optic 
nerve axons before the ﬁ  rst visual ﬁ  eld defect is detectable 
using standard automated perimetry (Pederson and Anderson 
1980; Zeyen and Caprioli 1993).
OH is characterized by an increase of IOP without any 
visual ﬁ  eld, ONH, and retinal nerve ﬁ  bre layer changes 
(European Glaucoma Society 2003). In other words OH 
can be a ﬁ  rst step forward the glaucoma in most patients, 
but not all OH patients will change to glaucoma. Indeed, 
in the ocular hypertension treatment study (OHTS), it was 
found that after a follow-up of 5 or 7 years some OH subjects 
changed to glaucoma even if patients were treated or not 
(Van der Walk et al 2005). Obviously the percentage was 
different and in particular among the OH patients treated 
with topical hypotonic medication about 5% changed to 
glaucoma, while in the other group which did not receive 
any medication the percentage change was 9% (Kass et al 
2002). However, it is still not clear when and which OH 
patients need to be treated.
Both in POAG and OH patients, the main risk fac-
tor for progression is an elevated IOP which can cause 
damage to the ONH and then to the visual ﬁ  eld. Some 
clinical trials have shown that decreasing the IOP can be 
useful for slowing down glaucoma progression (CNTGS 
1998; AGIS Investigators 2000; Kass et al 2001; Heijl 
et al 2002; Leske et al 2007), and IOP has been the only 
treatable risk factor until now (European Glaucoma 
Society 2003). Thus the treatment of glaucoma focuses 
on the reduction of IOP with drugs, lasers, or surgery. 
Over the past few years, there has been a gradual shift 
in the choice of ﬁ  rst-line medical therapy. Six different 
classes of IOP-lowering molecules are currently avail-
able, including alpha adrenergic agonists, beta-blockers, 
CAI, parasympathomimetics, prostaglandin analogues, 
and sympathomimetics. The efﬁ  cacy differs among these 
classes, ranging from about 30% for the prostaglandins/
prostamides to about 18% for the topical CAI (European 
Glaucoma Society 2003).
Clinically, all types of IOP-lowering medications can 
be used as the ﬁ  rst choice, as European Glaucoma Society 
guidelines suggest. If the ﬁ  rst-chosen medication alone does 
not control glaucoma, adjunctive therapy in the form of 
other topical agents can be added to the therapeutic regimen. 
However, when the first choice is not effective and/or 
tolerated in any individual patient, any of the other topical 
agents can be substituted as monotherapy.
When choosing the medical treatment for glaucoma, it 
is important to understand not only the aims of therapy, but 
also the mode of action, side effects, and contraindications 
of each individual medication (European Glaucoma Society 
2003). Many antiglaucoma drugs are available, and the 
choice of therapy must take into account quality of life, cost, 
and compliance. If more than two topical medications are 
required to control the IOP, other forms of therapy, such as 
laser trabeculoplasty, or surgery, should be considered.
The reduction of IOP can differ based on the IOP base-
line; however, the CNTGS showed that the reduction should 
be at least 30% to slow glaucoma progression (CNTGS 
1998). In contrast the AGIS Investigators showed that in the 
group of patients that maintained IOP at around 12 mmHg in 
all examinations during the 7-year follow-up, visual ﬁ  eld did 
not progress (Reis et al 2006). Leske et al (2007) evaluated 
separately patients with higher and lower baseline IOP to 
determine progression factors at the end of the Early Manifest 
Glaucoma Trial (EMGT) based on all EMGT patients. 
Patients with early open-angle glaucoma were randomized 
to argon laser trabeculoplasty plus betaxolol or no immedi-
ate treatment, and examined every 3 months for up to 11 
years. Treatment and follow-up continued to have a marked 
inﬂ  uence on IOP progression, regardless of baseline IOP. 
Other signiﬁ  cant factors were age, bilaterality, exfoliation, 
and disc hemorrhages. Lower systolic perfusion pressure, 
lower systolic blood pressure, and cardiovascular disease 
history emerged as new predictors, suggesting a vascular 
role in glaucoma progression. A new risk factor was a thin-
ner central corneal thickness (Leske et al 2007), but its role 
is still under debate as a confounding factor.
Also the OHTS showed that topical ocular hypotensive 
medication is effective in delaying or preventing the onset 
of POAG in individuals with elevated IOP (OH) and no 
evidence of glaucomatous damage (European Glaucoma 
Society 2003).Clinical Ophthalmology 2008:2(3) 520
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These data show that IOP reduction is fundamental in 
POAG and OH to delay the onset or prevent the onset of 
POAG in OH or the progression of the damage in POAG. 
Brinzolamide can be used alone or in combination with other 
medication to treat these patients.
The main ocular effect of brinzolamide is on IOP: in the 
ciliary epithelium, the inhibition of CA-II slows the forma-
tion of bicarbonate ions and their secretion into the posterior 
chamber of the eye. This reduces the sodium transport into the 
posterior chamber and decreases aqueous humor production, 
resulting in lower IOP (Maren 1967). Interestingly, CA is a 
highly efﬁ  cient enzyme, and it has been estimated that more 
than 99% of CA activity must be inhibited in order to sup-
press aqueous production to lower IOP measurably (Maren 
1967). The efﬁ  cacy of brinzolamide 1% and dorzolamide 
2% was compared in 25 normal subjects: brinzolamide 
reduced daytime aqueous ﬂ  ow by 0.47 μL/min and night-time 
aqueous ﬂ  ow by 0.16 μL/min, while dorzolamide reduced 
aqueous ﬂ  ow by 0.34 μL/min and by 0.10 μL/min, respec-
tively. However, the relative reductions of aqueous ﬂ  ow 
achieved by brinzolamide and dorzolamide were similar for 
both medications (Ingram and Brubaker 1999).
In monotherapy
In a meta-analysis, Van der Valk et al (2005) estimated the 
IOP reduction achieved by the most frequently prescribed 
glaucoma drugs and a placebo in a meta-analysis of random-
ized clinical trials: they found that the highest reduction of 
IOP achieved by brinzolamide was of 17%.
Wang et al (2004) conducted a small, prospective, 
double-masked study comparing brinzolamide 1% bid with 
timolol 0.5% bid in 50 patients with open-angle glaucoma. 
After 6 weeks of treatment, IOP dropped 4.8 mmHg (17%) 
in brinzolamide-treated eyes and 5.7 mmHg (19.7%) in 
timolol-treated eyes (p  0.05).
Adjunctive to beta-blocker
Shin (2000) compared the efﬁ  cacy of brinzolamide 1% (tid) 
and timolol 0.5% (bid) to timolol 0.5 (bid) and placebo (tid) 
in patients with open-angle glaucoma or OH. After 1 month 
of timolol, patients added either brinzolamide or placebo for 
3 months; mean IOP reductions after the addition of brinzol-
amide to timolol ranged from 3.3 to 4.1 mmHg (statistically 
signiﬁ  cant compared with both baseline and placebo).
Adjunctive to prostaglandin
As we well know, prostaglandin derivatives improve uveo-
scleral outﬂ  ow, but they also increase the activity of CA 
in ciliary epithelium with a secondary increase in aqueous 
humor secretion (Martinez-de-la-Casa et al 2004), causing 
a slight reduction in the efﬁ  cacy of prostaglandin analogues.
Theoretically, topical CAI decrease IOP by inhibiting CA-II 
(DeSantis 2000), thus improving prostaglandin efﬁ  cacy as 
well as reducing IOP.
Clinically in all adjunctive studies, a signiﬁ  cant reduction 
of IOP was observed. Shoji et al (2005) added brinzolamide 
to once-daily latanoprost 0.005% in a small (n = 14), uncon-
trolled, open-label study of POAG. Mean IOP signiﬁ  cantly 
(p  0.01) decreased by 20%, 21.1%, and 23.5% after 1, 2, 
and 3 months of treatment, respectively. Also in patients 
with normal-tension glaucoma, Nakamoto and Yasuda 
(2007) compared the efﬁ  cacy of latanoprost alone in one eye 
with latanoprost plus brinzolamide in the fellow eye. Mean 
diurnal (p  0.001) and nocturnal (p  0.05) IOP and the 
mean circadian IOP reduction from washout (p  0.01) were 
signiﬁ  cantly reduced more in the brinzolamide adjunct group 
(17.1%) than the latanoprost monotherapy group (13.6%).
In a multicenter, randomized, double-masked, parallel 
group comparison study, Franks et al (2006) compared 
the effect of brinzolamide 1% bid or timolol 0.5% bid 
when added to travoprost. After 3 months, no signiﬁ  cant 
(p = 0.96) difference in the IOP reduction was found 
between groups. Hollo et al (2006) found that patients 
receiving combined travoprost ophthalmic solution 0.004% 
and brinzolamide ophthalmic suspension 1% therapy had 
lower IOP values than those on travoprost monotherapy 
(p  0.0001). Combined therapy resulted in a signiﬁ  cantly 
greater percentage of patients achieving IOP of 18 mmHg 
or less (p  0.0001).
Feldman et al (2007) compared the efﬁ  cacy of brinzolamide 
1% bid with brimonidine 0.15% bid when added to travo-
prost once daily: after 3 months of treatment, a reduction 
of 2.7 mmHg was found in the brinzolamide group and of 
2.1 mmHg in the brimonidine group (signiﬁ  cant, p = 0.035).
Reis et al (2006) compared the additive efﬁ  cacies of 
brinzolamide 1%, brimonidine 0.2%, or timolol 0.5%, each 
dosed twice daily, when added to travoprost 0.004% once 
daily. Mean adjunctive IOP reduction seen with brinzol-
amide (4.2 mmHg, 22.7%) was statistically equivalent to 
that seen with timolol (3.9 mmHg, 20.2%) (p  0.05) and 
both were signiﬁ  cantly (p  0.02) greater than that seen with 
brimonidine (2.3 mmHg, 13.4%).
Martinez-de-la-Casa et al (2004) compared the IOP-
lowering efﬁ  cacy of concomitant therapy with travoprost 
once daily and brinzolamide twice daily versus once-daily 
dosing of the latanoprost/timolol ﬁ  xed combination. Mean Clinical Ophthalmology 2008:2(3) 521
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diurnal IOP was lower in the travoprost plus brinzolamide 
group than in the latanoprost/timolol group at 1 month 
(p = 0.041), 2 months (p = 0.046), and 3 months (p = 0.015). 
The IOP differences ranged from 0.8 to 1.2 mmHg.
However, there is some published evidence that the 
pathophysiology of glaucoma is multifactorial, and that 
impaired blood ﬂ  ow has a role in the disease process (Leske 
et al 1995; Tielsch et al 1995; Bonomi et al 2000; Quigley 
et al 2001). Low diastolic perfusion pressure has been linked 
to a higher incidence of glaucoma in a population-based 
study. Furthermore, disc hemorrhage has been identiﬁ  ed as a 
risk factor for disease progression in several studies (Budenz 
et al 2006; Leske et al 2003). Also, conditions related 
to vasospasm are sometimes found in patients with 
glaucoma, especially in normal-tension glaucoma. Vascular 
dysregulation could be one of the most important prognostic 
factors for following some patients. The inconstant ONH 
perfusion could activate the astroglia to produce some 
molecules that normally they do not produce or produce in 
low levels (Grieshaber et al 2007).
As Schulzer and Drance (1987) showed, the use of 
the magic number of 21 mmHg to divide normal-tension 
glaucoma (NTG) from high-tension glaucoma (HTG) is not 
sufﬁ  cient: indeed they found that other risk factors could 
be useful to divide POAG subgroups. Similar results using 
a different approach were obtained by Nicolela and Drance 
(1996) who reviewed about 1000 ONH slides of glaucoma-
tous patients to divide them into 4 glaucomatous subgroups: 
focal ischemic glaucoma, senile glaucoma, myopic glau-
coma, and concentric excavation glaucoma. They selected 
about 100 pure aspect optic discs that were included in one 
of these four subgroups. Finally, they checked the clinical 
features of each subgroup and found signiﬁ  cant differences 
in IOP values, vasospatic symptoms, and visual ﬁ  eld defects, 
suggesting that IOP was still an important risk factor to 
treat, but other factors were involved in the pathogenesis 
of the disease.
Brinzolamide could have a secondary possible effect on 
ocular ﬂ  ow. Sampaolesi et al (2001) compared the ONH 
circulation in healthy eyes, OH, and glaucoma eyes and 
found that blood ﬂ  ow was decreased in OH and glaucoma 
eyes compared with normal ones. Brinzolamide restored 
ONH blood ﬂ  ow to normal levels in OH eyes, but it did not 
change with brinzolamide therapy, most probably due to the 
loss of connective tissue.
However, Kothy and Hollo (2001) investigated the 
potential in vivo inﬂ  uence of different topical glaucoma 
medications on the diameter of retinal arterioles of healthy 
volunteers and glaucoma patients through the use of a retinal 
vessel analyzer (RVA, Imedos GmbH, Weimar, Germany) 
and found no significant changes in arteriole diameter 
at 2 hours after instillation of the topical antiglaucoma 
drugs (ie, brinzolamide 1%, timolol 0.5%, betaxolol 0.5%, 
brimonidine 0.2%, latanoprost 0.005%).
Siesky et al (2006) reported that eyes with POAG, treated 
with brinzolamide, beneﬁ  ted from higher diastolic perfusion 
pressures than eyes treated with dorzolamide. Thirteen sub-
jects were enrolled in a masked crossover study consisting of 
3 months of therapy with each drug. There were no statisti-
cally signiﬁ  cant differences in IOP, heart rate, mean arterial 
pressure, or systolic blood pressure, but diastolic perfusion 
pressure was higher in left eyes (although comparable in 
right eyes) of subjects treated with brinzolamide versus 
dorzolamide.
Using the Heidelberg Retina Flowmeter in a prospective 
study on 20 glaucomatous patients, Iester (2003) found that 
after brinzolamide treatment a 19% decrease in IOP was 
obtained and a concomitant improvement of the retinal blood 
ﬂ  ow was obtained at the superior and inferior peripapillary 
area. The improvement of the retinal blood ﬂ  ow ranged from 
13.15 % to 16.6%. In 30 normal human volunteers, Kaup 
et al (2004) found that eyes treated with brinzolamide had 
no measurable changes in retrobulbar hemodynamic by color 
Doppler, but did show a signiﬁ  cantly reduced arteriovenous 
passage time compared with placebo, as determined by video 
ﬂ  uorescein angiogram.
Theoretically, CAI could give rise to metabolic acidosis, 
with secondary vasodilatation and improvement of blood ﬂ  ow. 
Systemic acidosis can occur in the setting of oral CAI therapy, 
and local acidosis within ocular tissues is theoretically possible 
with topical CAI therapy, with the potential for a local increase 
in ocular blood ﬂ  ow (Kaur et al 2002). Topical and systemic 
CAI have been shown to improve parameters related to ocular 
blood ﬂ  ow (Harris et al 1996, 1999; Barnes et al 2000). In 
particular, because systemic CAI also results in altered CO2 
clearance and pH levels (Sponsel and Shipman 1997), an 
increase in tissue PCO2 might promote local vasodilatation. 
Furthermore, several authors found that acetazolamide is 
capable of increasing cerebral blood ﬂ  ow in a dose-dependent 
manner, which was attributed to extracellular acidiﬁ  cation 
(Severinghaus and Cotev 1968; Hauge et al 1983; Volstrup 
et al 1984; Faraci et al 1987; Ringelstein et al 1992).
Even if local CAIs accumulate inside the red blood cells 
because of their high afﬁ  nity for some proteins of red cells and 
plasma (Harris et al 1996; Costa et al 2003), it has been shown 
that topical CAI did not affect the retrobulbar hemodynamic Clinical Ophthalmology 2008:2(3) 522
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parameters, while they enhanced the retinal blood ﬂ  ow velocity 
indices, improved retinal blood flow, and increased the 
capillary velocity in the superﬁ  cial vessels of the ONH.
Several studies have shown blood flow or blood 
velocity differences between normal healthy subjects and 
glaucomatous ones (Galassi et al 1992; Gherghel et al 
2000); and epidemiological studies have disclosed an 
increased risk for glaucoma when ocular perfusion was 
low (Tielsch et al 1995; Bonomi et al 2000). Therefore, 
the secondary vasoactive effect of brinzolamide could 
be useful in glaucoma since evidence is growing that in 
some glaucoma patients vascular dysregulation and lower 
perfusion pressure are important risk factors (Harris et al 
1996, 1999; Carlsson  et al  2000).
In conclusion, topical CAI treatment has an efﬁ  cacy in 
IOP-lowering that ranges from 15% to 20%. Published data 
show that brinzolamide can be used as ﬁ  rst-line medication, 
even if other medications have a higher efﬁ  cacy, with few 
side effects, and that it is a good adjunctive treatment. In 
those patients in which IOP must be reduced more than 30%, 
brinzolamide can be combined with either prostaglandin ana-
logues or with beta-blockers. In the near future new formula-
tions with brinzolamide will be on the market. In particular 
it will be combined with a beta-blocker or a prostaglandin 
analogue. In the former ﬁ  xed combination, both molecules 
work to decrease IOP by suppressing the production of aque-
ous humor, but in the latter the target of the two medications 
to decrease IOP is different. In particular, topical CAI should 
be able to inhibit the activity of CA in the ciliary epithelium 
which the prostaglandins tend to increase (Shoji et al 2005; 
Nakamoto and Franks 2006; Yasuda 2007).
In some types of glaucoma patients with a vascular dys-
regulation, topical CAI could have a double effect: to reduce 
the IOP and to improve the ocular blood ﬂ  ow. However, it is 
still controversial whether topical CAI can improve ocular 
blood ﬂ  ow, and we have to consider the possibility that the 
improvement of the ocular ﬂ  ow could be also be due to 
simply IOP reduction. Even if some clinical studies showed 
that brinzolamide could improve blood ﬂ  ow, no long-term 
trial has been performed to answer this question.
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